July 5, 2023 06:51 AM EDT
Bioregnum

The H1 pic­ture: Biotech’s vi­tal signs show some life — with one big ex­cep­tion

This past six months, the num­bers have start­ed to track up­ward in biotech — and we’re not just talk­ing about M&A here.

We’re start­ing to see …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Judge halts some NIH cuts af­ter 22 states sue

Mer­ck KGaA con­firms in­ter­est in ac­quir­ing can­cer biotech Spring­Works

Eli Lil­ly inks $630M deal for Phase 1 MASH can­di­date

Decade af­ter $8B deal, Roche of­floads In­ter­Mune to mys­te­ri­ous spe­cial­ty phar­ma

Boehringer In­gel­heim touts suc­cess in sec­ond Phase 3 lung fi­bro­sis tri­al

sponsored

Re­duc­ing risk in drug de­vel­op­ment: The im­por­tance of val­i­dat­ed MRD test­ing in lym­phoid can­cers

A service from the Financial Times